Abstracts Archive - Page 106 of 2607 - ACR Meeting Abstracts

Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…
Abstract Number: 1141 • ACR Convergence 2025
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
Sadiq Umar¹, Kasey Leung² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent form of inflammatory arthritis, with rising global incidence. It results from the deposition of monosodium urate (MSU) crystals in…
Abstract Number: 1135 • ACR Convergence 2025
A Gain-of-Function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular PPi and Citrate
richette pascal¹, christophe Duranton², Thomas Pinna³, Manon Ricquebourg⁴, LATOURTE Augustin⁵, Thomas Bardin⁶, Valérie Bousson⁷, Hang-Korng Ea⁸, Isabelle Rubera⁹ and Corinne Collet¹⁰, ¹Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ²CNRS-UMR ⁷³⁷⁰ - Laboratoire de Physiomedecine moléculaire, Nice, Rhone-Alpes, France, ³INSERM U¹¹³², PARIS, Ile-de-France, France, ⁴Lariboisiere Hospital, INSERM U¹¹³², Paris, France, ⁵Rheumatology Department, Lariboisiere Hospital, Paris, France, ⁶Lariboisiere Hospital, Department of Rheumatology, Paris, France, ⁷Radiology Department, Lariboisiere Hospital, Paris, France, ⁸INSERM U¹¹³², Lariboisiere Hospital, Paris, France, ⁹CNRS-UMR ⁷³⁷⁰ - Laboratoire de Physiomedecine moléculaire, Nice, France, ¹⁰Reference Center for Skeletal Dysplasia, INSERM UMR ¹¹⁶³, Paris, France
Background/Purpose: To identify novel pathogenic variants associated with chondrocalcinosis (CC), we systematically screened individuals with a family history of CPPD using an NGS panel. Among…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Guishan Liu¹, Jingyuan zhang², jin Xu², JiaYuan Dai² and Min Shen², ¹Peking union medical college hospital, Beijing, Beijing, China (People's Republic), ²Peking union medical college hospital, Beijing, China (People's Republic)
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…
Abstract Number: 1108 • ACR Convergence 2025
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Laura Cappelli¹, Pankti Reid², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Namrata Singh¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Ami Shah¹⁵ and Clifton Bingham¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Chicago Medical Center, Chicago, IL, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Washington, Bellevue, WA, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies commonly used to treat malignancies but can cause flares or unrelated immune-related adverse events (irAEs) in patients…
Abstract Number: 1161 • ACR Convergence 2025
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Javier Narváez¹, Orfa Barrios², Pol Maymó-Paituvi³, JUAN JOSE ALEGRE SANCHO⁴, Ivan Castellví⁵, Vanesa Vicens Zygmunt⁶, Guadalupe Bermudo⁷, Laia De Daniel Bisbe³, Martí Aguilar-Coll⁸, Montserrat Roig Kim³, Joan Miquel Nolla³ and Maria Molina-Molina⁷, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital Nacional Arzobispo Loayza, Lima, Peru, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁶Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁸Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…
Abstract Number: 1156 • ACR Convergence 2025
Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort
elena Joerns¹, Sara Achenbach¹, Cynthia Crowson², eva carmona¹, Robert Vassallo³, John Joerns¹, Vanessa Kronzer³, John Davis³ and Elena myasoedova³, ¹Mayo Clinic, Rochester, ²Mayo Clinic, Stewartvillle, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial lung disease (ILD) with features of autoimmunity, yet patients do not fulfill criteria…
Abstract Number: 1162 • ACR Convergence 2025
Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease
Javier Narváez¹, Pol Maymó-Paituvi², Vanesa Vicens Zygmunt³, Guadalupe Bermudo⁴, Martí Aguilar-Coll⁵, Montserrat Roig Kim², Laia De Daniel Bisbe², Joan Miquel Nolla² and Maria Molina-Molina⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: There is increasing evidence of the association between interstitial lung disease (ILD) and ANCA positivity without other manifestations of systemic vasculitis. The prognosis of…
Abstract Number: 1057 • ACR Convergence 2025
Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
Rebecca Summit¹, Dylan Tierney², Taussia Boadi², Tyler Green², Karli Retzel², Virginia Bills², Nancy Shadick², Leah Santacroce³, Sara Schoenfeld⁴ and Candace Feldman⁵, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Mass General Hospital, Boston, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston
Background/Purpose: Social risk factors, such as housing instability, influence care access and outcomes in people with rheumatic conditions. In June 2022, 9 rheumatology clinics in…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 1157 • ACR Convergence 2025
Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Ella Steiner¹, Ioana Andreica², Stefanie Reale³, Gianna Chierego⁴, Philipp Köhler⁵, Sonja Zapke⁴, Benjamin Wilde⁶, David Kiefer⁷, Philipp Sewerin², Hilal Kavruk⁵, Dimitra Karagkiozidou⁵, Panagiotis Ermeidis⁵, Barbara Guminski⁵, Andreas Kribben⁶, Jürgen Braun⁸, Xenofon Baraliakos⁹ and Uta Kiltz⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶University Hospital, Nephrology, Essen, Essen, Germany, ⁷Private practice of rheumatology, Hattingen, Germany, ⁸Ruhr-University, Bochum, Germany; and Rheumatologische Versorgungszentrum (RVZ) Steglitz, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common among older adults, with a lifetime risk of 25%. The risk is particularly increased in individuals with immunosuppression such…
Abstract Number: 1171 • ACR Convergence 2025
VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy
Marta López¹, Paula Garcia Escudero², Berta Magallares³, Meritxell Salles Lizarzaburu⁴, Dolly Viviana Fiallo Suárez⁵, Iñigo Rúa-Figueroa⁶, Isla Morante Bolado⁷, Elena Aurrecoechea⁸, Eugenia Enriquez⁹, Carolina Merino¹⁰, Santos Castañeda¹¹, Irene Monjo Henry¹², César Antonio Egües Dubuc¹³, Elena María Oliver García¹⁴, Alicia Garcia¹⁵, Judit Font-Urgelles¹⁶, Cristina Corrales¹⁷, Lourdes Villalobos¹⁸, Alina-Lucica Boteanu¹⁹, Ignacio Vázquez Gómez²⁰, Diego Dios²¹, Clara Garcia Belando²², Beatriz Frade Sosa²³, Delia Reina²⁴, Marta Ibañez²⁵, Irene Carrion²⁶, Maria Rodriguez²⁷, cristiana Sieiro²⁸, Francisco Javier Toyos²⁹, Alberto Mariano³⁰, Clara Moriano³¹, Rafael B. Melero-González³², Paloma Vela Casasempere³³, Jose Alberto Miranda³⁴, Giuliano Boselli³⁵, Jose Angel Hernandez³⁶, Ernesto Trallero³⁷, Elena Riera Alonso³⁸ and Jaime Calvo³⁹, ¹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ²H.U.Araba, Vitoria, ³Hospital de Sant Pau, Bareclona, ⁴Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ⁵H.U. Doctor Negrín, Gran Canarias, ⁶Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁷Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁸H. Sierrallana, Santander, ⁹Clínica Universidad de Navarra, Madrid, Spain, ¹⁰Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ¹⁴H.C. U. Lozano Blesa, Zaragoza, ¹⁵Rheumatologist, La Laguna, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹⁸Ramon y Cajal Hospital, MADRID, Spain, ¹⁹H.U. Ramón y Cajal, Madrid, Spain, ²⁰H.U. Doctor Peset, Valencia, ²¹H.U de A Coruña, A Coruña, Spain, ²²H.C. U. Virgen de la arrizaca, Murcia, ²³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁵Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁶Hospital del Mar, Barcelona, Spain, ²⁷H. Clínico San Carlos, Madrid, Spain, ²⁸Univrsity of Manchester, Manchester, United Kingdom, ²⁹Virgen Macarena University Hospital,, Sevilla, Spain, ³⁰Virgen del Rocío University Hospital, Sevilla, Spain, ³¹Hospital León, LEON, Castilla y Leon, Spain, ³²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ³³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³⁶Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ³⁷H. U. Vall d'Hebron, Barcelona, ³⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in UBA1 gene, characterized by systemic inflammation and haematologic abnormalities. Evidence regarding its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].